1887

Abstract

To investigate whether cytokine responses may have a bearing on the symptoms and outcome of parvovirus B19 infection, circulating cytokines were measured during acute infection (=51), follow-up of acute infection (=39) and in normal healthy controls (=50). At acute B19 virus infection (serum anti-B19 IgM-positive), patients ranged in age from 4 to 54 years, with a mean age of 28·2 years. The male:female ratio was 1:4·1 and symptoms were rash (=15), arthralgia (=31), fatigue (=8), lymphadenopathy (=4), foetal hydrops (=3), transient aplastic crisis (=2), neutropenia (=2), myelodysplasia (=1), thrombocytopenia (=1) and pancytopenia (=1). Of these patients, 39 were contacted after a follow-up period of 2–37 months (mean of 22·5 months). In comparison with normal controls, detectable IL-6 was associated with acute B19 virus infection (26%; =0·0003), but not with follow-up (6%; =0·16). Detection of interferon (IFN)-γ was associated with acute B19 virus infection (67%; <0·0001) and follow-up (67%; <0·0001). Detection of tumour necrosis factor (TNF)-α was associated with acute B19 virus infection (49%; <0·0001) and follow-up (56%; <0·0001). IL-1β was detected in acute infection (20%), but not at follow-up. At acute B19 virus infection, detection of serum/plasma IL-6 was associated with rheumatoid factor (=0·038) and IFN-γ (⩾7 pg/ml) was associated with fatigue in those patients of ⩾15 years of age (=0·022). At follow-up, fatigue was associated with IFN-γ (⩾7 pg/ml) and/or TNF-α (⩾40 pg/ml) (=0·0275). Prolonged upregulation of serum IFN-γ and TNF-α appears to represent a consistent host response to symptomatic B19 virus infection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-82-12-3011
2001-12-01
2020-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/82/12/0823011a.html?itemId=/content/journal/jgv/10.1099/0022-1317-82-12-3011&mimeType=html&fmt=ahah

References

  1. Anderson M. J., Higgins P. G., Davis L. R., Willman J. S., Jones S. E., Kidd I. M., Pattison J. R., Tyrrell D. A. J.. 1985; Experimental parvoviral infection in humans. Journal of Infectious Diseases152:257–265
    [Google Scholar]
  2. Bauder B., Suchy A., Gabler C., Weissenbock H.. 2000; Apoptosis in feline panleukopenia and canine parvovirus enteritis. Journal of Veterinary Medicine Series B47:775–784
    [Google Scholar]
  3. Choy E. H. S., Panayi G. S.. 2001; Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine344:907–916
    [Google Scholar]
  4. Chung Y. H., Jun H. S., Kang Y., Hirasawa K., Lee B. R., Van Rooijen H., Yoon J. W.. 1997; Role of macrophages and macrophage-derived cytokines in the pathogenesis of Kilham rat virus-induced autoimmune diabetes: diabetes-resistant biobreeding rats. Journal of Immunology159:466–471
    [Google Scholar]
  5. Coker A. L., Russell R. B., Bond S. M., Pirisi L., Liu Y., Mane M., Kokorina N., Gerasimova T., Hermonat P. L.. 2001; Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. Experimental and Molecular Pathology70:83–89
    [Google Scholar]
  6. Corcoran A., Doyle S., Waldron D., Nicholson A., Mahon B. P.. 2000; Impaired gamma interferon responses against parvovirus B19 by recently infected children. Journal of Virology74:9903–9910
    [Google Scholar]
  7. Cossart Y. E., Field A. M., Cant B., Widdow D.. 1976; Parvovirus-like particles in human sera. Lancet1:72–73
    [Google Scholar]
  8. Durigon E. L., Erdman D. D., Gary G. W., Pallansch M. A., Torok T. J., Anderson L. J.. 1993; Multiple primer pairs for polymerase chain reaction (PCR) amplification of human parvovirus B19 DNA. Journal of Virological Methods44:155–165
    [Google Scholar]
  9. Feldmann M., Maini R. N.. 2001; Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annual Review of Immunology19:163–196
    [Google Scholar]
  10. Franssila R., Soderlund M., Brown S. B., Spaan W. J. M., Seppala I., Hedman K.. 1996; IgG response to human parvovirus B19 infection. Clinical & Diagnostic Virology6:41–49
    [Google Scholar]
  11. Fukuda K., Straus S. E., Hickie I., Sharpe M. C., Dobbins J. G., Komaroff A. L.. The International Chronic Fatigue Syndrome Study Group 1994; The chronic fatigue syndrome: a comprehensive approach to its definition and study. Annals of Internal Medicine121:953–959
    [Google Scholar]
  12. Georg-Fries B., Biederlack S., Wolf J., zur Hausen H.. 1984; Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology134:64–71
    [Google Scholar]
  13. Goodbourn S., Didcock L., Randall R. E.. 2000; Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. Journal of General Virology81:2341–2364
    [Google Scholar]
  14. Holt I., Cooper R. G., Hopkins S. J.. 1991; Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. European Journal of Clinical Investigation21:479–484
    [Google Scholar]
  15. Hunter C. A., Reiner S. L.. 2000; Cytokines and T cells in host defense. Current Opinion in Immunology12:413–418
    [Google Scholar]
  16. Ikeda Y., Shinozuka J., Miyazawa T., Kurosawa K., Izumiya Y., Nishimura Y., Nakamura K., Cai J., Fujita K., Doi K., Mikami T.. 1998; Apoptosis in feline panleukopenia virus-infected lymphocytes. Journal of Virology72:6932–6936
    [Google Scholar]
  17. Ishii K. K., Takahashi Y., Kaku M., Sasaki T.. 1999; Role of human parvovirus B19 in the pathogenesis of rheumatoid arthritis. Japanese Journal of Infectious Diseases52:201–207
    [Google Scholar]
  18. Jordan J. A., Huff D., DeLoia J. A.. 2001; Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clinical and Diagnostic Laboratory Immunology8:288–292
    [Google Scholar]
  19. Kerr J. R.. 2000; Pathogenesis of human parvovirus B19 in rheumatic disease. Annals of the Rheumatic Diseases59:672–683
    [Google Scholar]
  20. Kerr J. R., O’Neill H. J., Deleys R. J., Wright C., Coyle P. V.. 1995; Design and production of a target-specific monoclonal antibody to parvovirus B19 capsid proteins. Journal of Immunological Methods180:101–106
    [Google Scholar]
  21. Kurtzman G. J., Frickhofen N. K., Kimball J., Jenkins D. W., Nienhuis A. W., Young N. S.. 1989; Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. New England Journal of Medicine321:519–523
    [Google Scholar]
  22. Lejeune F. J., Ruegg C., Lienard D.. 1998; Clinical applications of TNF-α in cancer. Current Opinion in Immunology10:573–580
    [Google Scholar]
  23. Mani S., Poo W. J.. 1996; Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. American Journal of Clinical Oncology19:149–153
    [Google Scholar]
  24. Mayor H. D., Drake S., Stahmann J., Mumford D. M.. 1976; Antibodies to adeno-associated satellite virus and herpes simplex virus in sera from cancer patients and normal adults. American Journal of Obstetrics and Gynecology126:100–104
    [Google Scholar]
  25. Moffatt S., Tanaka N., Tada K., Nose M., Nakamura M., Muraoka O., Hirano T., Sugamura K.. 1996; A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. Journal of Virology70:8485–8491
    [Google Scholar]
  26. Moffatt S., Yaegashi N., Tada K., Tanaka N., Sugamura K.. 1998; Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. Journal of Virology72:3018–3028
    [Google Scholar]
  27. Moss R. B., Mercandetti A., Vojdani A.. 1999; TNF-α and chronic fatigue syndrome. Journal of Clinical Immunology19:314–316
    [Google Scholar]
  28. Nigro G., Bastianon V., Colloridi V., Ventriglia F., Gallo P., D’Amati G., Koch W. C., Adler S. P.. 2000; Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clinical Infectious Diseases31:65–69
    [Google Scholar]
  29. Ohshima T., Iwana M., Ueno Y., Sugiyama F., Nakajima T., Fukamizu A., Yagami K.-i.. 1998; Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection. Journal of General Virology79:3067–3071
    [Google Scholar]
  30. Otto C. M., Drobatz K. J., Soter C.. 1997; Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis. Journal of Veterinary Internal Medicine11:65–70
    [Google Scholar]
  31. Patarca R., Klimas N. G., Lugtendorf S., Antoni M., Fletcher M. A.. 1994; Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clinical Infectious Diseases18 (Suppl. 1):S147–S153
    [Google Scholar]
  32. Pattison J. R., Jones S. E., Hodgson J., Davis L. R., White J. M., Stroud C. E., Murtaza L.. 1981; Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet1:664–665
    [Google Scholar]
  33. Penttila I. A., Harris R. J., Storm P., Haynes D., Worswick D. A., Marmion B. P.. 1998; Cytokine dysregulation in the post-Q-fever fatigue syndrome. Quarterly Journal of Medicine91:549–560
    [Google Scholar]
  34. Rasmussen A. K., Nielsen H., Andersen V., Barington T., Bendtzen K., Hansen M. B., Neilsen L., Pedersen B. K., Wiik A.. 1994; Chronic fatigue syndrome – a controlled cross-sectional study. Journal of Rheumatology21:1527–1531
    [Google Scholar]
  35. Rayet B., Lopez-Guerrero J. A., Rommelaere J., Dinsart C.. 1998; Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. Journal of Virology72:8893–8903
    [Google Scholar]
  36. Rommelaere J., Cornelis J. J.. 1991; Antineoplastic activity of parvoviruses. Journal of Virological Methods33:233–251
    [Google Scholar]
  37. Schlehofer J. R., Rentrop M., Mannel D. N.. 1992; Parvoviruses are inefficient in inducing interferon-β, tumor necrosis factor-α, or interleukin-6 in mammalian cells. Medical Microbiology and Immunology181:153–164
    [Google Scholar]
  38. Schwarz T. F., Roggendorf B., Hottentrager B., Modrow S., Deinhardt F., Middeldorp J.. 1990; Immunoglobulins in the prophylaxis of parvovirus B19 infection. Journal of Infectious Diseases162:1214
    [Google Scholar]
  39. Segovia J. C., Gallego J. M., Bueren J. A., Almendral J. M.. 1999; Severe leukopenia and dysregulated erythropoiesis in SCID mice persistently infected with the parvovirus minute virus of mice. Journal of Virology73:1774–1784
    [Google Scholar]
  40. Shade R. O., Blundell M. C., Cotmore S. F., Tattersall P., Astell C. R.. 1986; Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. Journal of Virology58:921–936
    [Google Scholar]
  41. Shingu M., Nagai Y., Isayama T., Naono T., Nobunaga M., Nagai Y.. 1993; The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clinical and Experimental Immunology94:145–149
    [Google Scholar]
  42. Sol N., Le Junter H., Vassias I., Freyssinier J. M., Thomas A., Prigent A. F., Rudkin B. B., Fichelson S., Morinet F.. 1999; Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by parvovirus B19. Journal of Virology73:8762–8770
    [Google Scholar]
  43. Sprecher-Goldberger S., Thiry L., Lefèbvre N., Dekegel D., de Halleux F.. 1971; Complement-fixation antibodies to adeno-associated viruses, cytomegaloviruses and herpes simplex viruses in patients with tumours and in control individuals. American Journal of Epidemiology94:351–358
    [Google Scholar]
  44. Takahashi Y., Murai C., Shibata S., Munakata Y., Ishii T., Ishii K., Saitoh T., Sawai T., Sugamura K., Sasaki T.. 1998; Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proceedings of the National Academy of Sciences, USA95:8227–8232
    [Google Scholar]
  45. von Poblotzki A., Gerdes C., Reischl U., Wolf H., Modrow S.. 1996; Lymphoproliferative responses after infection with human parvovirus B19. Journal of Virology70:7327–7330
    [Google Scholar]
  46. Wagner A. D., Goronzy J. J., Matteson E. L., Weyand C. M.. 1995; Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clinic Proceedings70:261–265
    [Google Scholar]
  47. Watanabe M., Shimamoto Y., Yamaguchi M., Inada S., Miyazaki S., Sato H.. 1994; Viral-associated haemophagocytosis and elevated serum TNF-α with parvovirus B19-related pancytopenia in patients with hereditary spherocytosis. Clinical and Laboratory Hematology16:179–182
    [Google Scholar]
  48. Zhou C., Trempe J. P.. 1999; Induction of apoptosis by cadmium and the adeno-associated virus Rep proteins. Virology261:280–287
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-82-12-3011
Loading
/content/journal/jgv/10.1099/0022-1317-82-12-3011
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error